Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Ebos Group Limited (EBO.AX)
AUD18.68
-0.12 (-0.64%)
AU ASX Healthcare Medical - Distribution
Address
737 Bourke Street 3008
Docklands, VIC, AU
Docklands, VIC, AU
CEO
Adam Luke Hall
Website
ebosgroup.com
IPO
2013-12-05
ISIN NZEBOE0001S6
Also trades on
Australian Securities Exchange · EBO.AX (AUD)
New Zealand Exchange · EBO.NZ (NZD)
Other OTC · EBOSY (USD)
Description
EBOS Group Limited engages in the marketing, wholesale, and distribution of healthcare, medical, pharmaceutical, and animal care products in Australia, Southeast Asia, and New Zealand. It operates through Healthcare and Animal Care segments. The company provides healthcare logistics; medication management solutions; pharmacy management software; loyalty, generics, compliance, business intelligence, and store software services; and health communications, programs, and consultancy services. It also offers community based health care services and programs; vitamins, minerals and supplements, herbal and fruit teas, and natural toothpastes, as well as functional foods, including molasses and manuka honey; Pharmacy Choice, a five step integrated retail program for independent pharmacies; and healthSAVE, a community pharmacy banner that helps members drive their retail businesses. Further, it offers healthcare distribution, warehousing, clinical trial management, and product registration services; clinical trial logistics; aesthetic healthcare devices, medical-grade cosmeceuticals, and injectables; and surgical devices and medical consumables. Additionally, the company provides pet nutrition, treats, clean-up, and grooming products and accessories; and wholesales veterinary products. The company was formerly known as Early Bros Dental & Surgical Supplies Ltd. and changed its name to EBOS Group Limited in 1986. EBOS Group Limited was incorporated in 1922 and is headquartered in Docklands, Australia.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
AUD18.68
-0.12 (-0.64%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
116.3K
Beta
0.16
Float Shares
194.82M
Free Float %
95.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.05% | -1.87% | -5.84% | -18.63% | -34.29% | -31.09% | -52.65% | -57.64% | -47.47% | +8.60% | +96.27% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
18.68
DCF (Unlevered)
48.64
+160.4%
DCF (Levered)
41.37
+121.5%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
67% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 3 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
Quality scores
Altman Z-Score
4.53
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
5 / 5
High
ROE Score
4 / 5
High
ROA Score
4 / 5
High
D/E Score
1 / 5
Low
P/E Score
2 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Distribution: +5.6%-8.3% Q4'25: +7.3% (vs Q4'23)
-
EPS growth Medical - Distribution: +4.9%-24.0% Q4'25: -12.8% (vs Q4'23)
-
FCF margin FCF growth · Medical - Distribution: +37.6%+2.6% Q4'25: -0.2% (vs Q4'23)
-
EBIT margin Medical - Distribution: +3.0%+3.2% ★ Q4'25: +2.8% (vs Q4'23)
-
ROIC Medical - Distribution: +5.7%+6.7% ★ Q4'25: +11.9% (vs Q4'23)
-
Share dilution Medical - Distribution: +0.0%+2.7% Q4'25: +7.2% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Distribution: 0.87×3.01× Q4'25: 2.16× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Jun 2000 actual |
Jun 2003 actual |
Jun 2004 actual |
Jun 2005 actual |
Jun 2006 actual |
Jun 2007 actual |
Jun 2008 actual |
Jun 2009 actual |
Jun 2010 actual |
Jun 2011 actual |
Jun 2012 actual |
Jun 2013 actual |
Jun 2014 actual |
Jun 2015 actual |
Jun 2016 actual |
Jun 2017 actual |
Jun 2018 actual |
Jun 2019 actual |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 10 Rev. Ana. 4 EPS Ana. |
Jun 2027 10 Rev. Ana. 4 EPS Ana. |
Jun 2028 4 Rev. Ana. 2 EPS Ana. |
Jun 2029 5 Rev. Ana. 1 EPS Ana. |
Jun 2030 5 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 78.92M (-100.0%)
|
224.02M
est: 224.13M (-0.1%)
|
227.66M
est: 236.83M (-3.9%)
|
280.26M
est: 293.38M (-4.5%)
|
300.30M
est: 313.50M (-4.2%)
|
307.00M
est: 310.98M (-1.3%)
|
1.09B
est: 1.10B (-0.6%)
|
1.34B
est: 1.38B (-2.9%)
|
1.37B
est: 1.41B (-3.1%)
|
1.34B
est: 1.39B (-3.3%)
|
1.43B
est: 1.44B (-0.9%)
|
1.54B
est: 1.95B (-21.1%)
|
5.76B
est: 5.76B (-0.1%)
|
6.07B
est: 5.35B (+13.5%)
|
7.10B
est: 6.34B (+12.0%)
|
7.63B
est: 7.33B (+4.0%)
|
7.61B
est: 7.08B (+7.5%)
|
7.25B
est: 6.98B (+3.9%)
|
9.38B
est: 8.75B (+7.3%)
|
9.89B
est: 9.14B (+8.1%)
|
11.90B
est: 10.35B (+15.0%)
|
13.32B
est: 12.18B (+9.3%)
|
14.41B
est: 14.42B (-0.1%)
|
13.21B
est: 13.11B (+0.7%)
|
14.64B
14.15B – 14.86B
+11.7% YoY
|
15.24B
14.71B – 15.61B
+4.1% YoY
|
15.84B
15.30B – 16.15B
+4.0% YoY
|
16.84B
16.26B – 17.17B
+6.3% YoY
|
17.82B
17.21B – 18.17B
+5.8% YoY
|
| EBITDA |
6.37M
est: 3.35M (+90.2%)
|
13.03M
est: 19.29M (-32.5%)
|
15.65M
est: 10.72M (+46.0%)
|
19.58M
est: 15.40M (+27.2%)
|
21.70M
est: 15.21M (+42.6%)
|
18.84M
est: 18.50M (+1.9%)
|
33.63M
est: 50.40M (-33.3%)
|
38.71M
est: 30.80M (+25.7%)
|
45.74M
est: 28.02M (+63.2%)
|
41.13M
est: 34.29M (+19.9%)
|
46.81M
est: 41.96M (+11.6%)
|
57.66M
est: 48.73M (+18.3%)
|
176.67M
est: 91.48M (+93.1%)
|
198.99M
est: 99.10M (+100.8%)
|
227.98M
est: 151.49M (+50.5%)
|
236.51M
est: 191.06M (+23.8%)
|
268.58M
est: 172.29M (+55.9%)
|
264.65M
est: 177.65M (+49.0%)
|
349.59M
est: 227.19M (+53.9%)
|
383.52M
est: 224.03M (+71.2%)
|
440.15M
est: 240.11M (+83.3%)
|
630.86M
est: 242.45M (+160.2%)
|
650.42M
est: 250.99M (+159.1%)
|
579.91M
est: 466.26M (+24.4%)
|
776.37M
750.59M – 787.79M
+66.5% YoY
|
808.03M
780.01M – 827.76M
+4.1% YoY
|
840.01M
811.48M – 856.53M
+4.0% YoY
|
892.76M
862.44M – 910.32M
+6.3% YoY
|
944.69M
912.61M – 963.27M
+5.8% YoY
|
| EBIT |
—
est: 2.60M (-100.0%)
|
11.21M
est: 18.19M (-38.4%)
|
13.67M
est: 9.87M (+38.4%)
|
17.02M
est: 13.49M (+26.2%)
|
20.04M
est: 16.03M (+25.0%)
|
17.13M
est: 18.50M (-7.4%)
|
30.88M
est: 50.40M (-38.7%)
|
34.70M
est: 30.80M (+12.7%)
|
41.55M
est: 28.02M (+48.3%)
|
37.72M
est: 34.29M (+10.0%)
|
43.09M
est: 33.62M (+28.2%)
|
51.81M
est: 48.55M (+6.7%)
|
155.66M
est: 145.46M (+7.0%)
|
174.88M
est: 160.87M (+8.7%)
|
203.29M
est: 203.04M (+0.1%)
|
210.67M
est: 238.81M (-11.8%)
|
233.97M
est: 210.19M (+11.3%)
|
230.46M
est: 222.19M (+3.7%)
|
271.56M
est: 294.14M (-7.7%)
|
304.78M
est: 290.78M (+4.8%)
|
352.81M
est: 311.65M (+13.2%)
|
480.18M
est: 314.69M (+52.6%)
|
509.61M
est: 325.78M (+56.4%)
|
421.73M
est: 468.91M (-10.1%)
|
524.39M
506.98M – 532.11M
+11.8% YoY
|
545.78M
526.85M – 559.10M
+4.1% YoY
|
567.38M
548.11M – 578.54M
+4.0% YoY
|
603.01M
582.53M – 614.87M
+6.3% YoY
|
638.09M
616.41M – 650.63M
+5.8% YoY
|
| Net Income |
188.0K
est: 21.13M (-99.1%)
|
-110.0K
est: 12.37M (-100.9%)
|
8.40M
est: 6.86M (+22.4%)
|
9.02M
est: 9.67M (-6.8%)
|
11.55M
est: 9.71M (+18.9%)
|
10.32M
est: 12.45M (-17.1%)
|
16.66M
est: 34.89M (-52.2%)
|
19.73M
est: 22.82M (-13.6%)
|
23.44M
est: 20.70M (+13.2%)
|
31.58M
est: 22.42M (+40.9%)
|
27.95M
est: 32.54M (-14.1%)
|
28.21M
est: 37.67M (-25.1%)
|
92.07M
est: 79.22M (+16.2%)
|
105.94M
est: 95.11M (+11.4%)
|
127.00M
est: 124.64M (+1.9%)
|
132.85M
est: 151.05M (-12.0%)
|
149.56M
est: 134.30M (+11.4%)
|
144.07M
est: 139.82M (+3.0%)
|
173.95M
est: 185.50M (-6.2%)
|
199.09M
est: 181.44M (+9.7%)
|
224.64M
est: 194.46M (+15.5%)
|
275.74M
est: 196.36M (+40.4%)
|
296.71M
est: 203.28M (+46.0%)
|
231.66M
est: 290.20M (-20.2%)
|
260.72M
256.62M – 266.65M
-10.2% YoY
|
270.26M
254.94M – 288.00M
+3.7% YoY
|
300.85M
287.57M – 308.54M
+11.3% YoY
|
292.22M
279.32M – 299.69M
-2.9% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
—
est: 3.35M (-100.0%)
|
2.14M
est: 4.73M (-54.8%)
|
2.09M
est: 2.65M (-21.0%)
|
2.38M
est: 3.00M (-20.7%)
|
28.11M
est: 3.51M (+700.7%)
|
28.85M
est: 13.20M (+118.5%)
|
58.72M
est: 97.70M (-39.9%)
|
66.79M
est: 80.43M (-17.0%)
|
65.70M
est: 70.57M (-6.9%)
|
56.33M
est: 63.18M (-10.8%)
|
68.13M
est: 58.50M (+16.5%)
|
88.37M
est: 92.10M (-4.1%)
|
231.94M
est: 248.16M (-6.5%)
|
237.26M
est: 241.36M (-1.7%)
|
263.95M
est: 281.34M (-6.2%)
|
295.59M
est: 316.81M (-6.7%)
|
357.37M
est: 300.64M (+18.9%)
|
357.61M
est: 335.27M (+6.7%)
|
347.69M
est: 459.99M (-24.4%)
|
382.43M
est: 363.90M (+5.1%)
|
467.06M
est: 390.01M (+19.8%)
|
578.28M
est: 393.82M (+46.8%)
|
619.43M
est: 407.69M (+51.9%)
|
632.72M
est: 555.69M (+13.9%)
|
621.45M
600.81M – 630.59M
+11.8% YoY
|
646.79M
624.36M – 662.58M
+4.1% YoY
|
672.38M
649.55M – 685.61M
+4.0% YoY
|
714.61M
690.34M – 728.67M
+6.3% YoY
|
756.18M
730.50M – 771.05M
+5.8% YoY
|
| EPS |
0.01
est: 0.11 (-92.8%)
|
0.00
est: 0.17 (-102.1%)
|
0.27
est: 0.21 (+28.5%)
|
-0.02
est: 0.24 (-109.5%)
|
0.36
est: 0.28 (+29.8%)
|
0.28
est: 0.25 (+12.3%)
|
0.33
est: 0.24 (+36.4%)
|
0.36
est: 0.27 (+34.4%)
|
0.41
est: 0.35 (+16.9%)
|
0.53
est: 0.31 (+69.5%)
|
0.47
est: 0.35 (+33.4%)
|
0.53
est: 0.54 (-2.6%)
|
0.63
est: 0.59 (+7.4%)
|
0.71
est: 0.60 (+17.9%)
|
0.84
est: 0.79 (+6.0%)
|
0.88
est: 0.86 (+2.1%)
|
0.98
est: 0.90 (+8.6%)
|
0.94
est: 0.92 (+2.7%)
|
1.06
est: 1.01 (+5.2%)
|
1.22
est: 1.14 (+7.1%)
|
1.22
est: 1.28 (-4.3%)
|
1.45
est: 1.43 (+1.1%)
|
1.54
est: 1.73 (-10.8%)
|
1.18
est: 1.50 (-21.4%)
|
1.32
1.30 – 1.35
-12.0% YoY
|
1.37
1.29 – 1.46
+3.7% YoY
|
1.52
1.46 – 1.56
+11.3% YoY
|
1.48
1.42 – 1.52
-2.9% YoY
|
—
— – —
-100.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-28 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-27 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-26 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-25 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-22 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-21 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-20 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-19 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-18 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-15 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-14 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-13 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-12 | B+ | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-11 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-08 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-07 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-06 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-05 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-04 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-01 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-30 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-29 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-28 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-27 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-24 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-23 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
706.04M
OE per share TTM
3.62
Owner's Yield
21.22%
Maintenance CapEx ratio
29.42%
Maint CapEx / Avg PPE
5.6%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Australian Shares Index ETF VAS.AX | 0.03% | 5.06M | 0.07% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
76.5K
Shares Outstanding
205.04M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Adam Luke Hall BCOMM | Chief Executive Officer | 4M | male |
| Alistair Gray | Chief Financial Officer | — | male |
| Brett Barons | Chief Executive Officer of Symbion & Healthcare Distribution | — | male |
| Grant Viney | Chief Executive Officer of EBOS Animal Care | — | male |
| Jacinta McCarthy | Executive General Manager of Human Resources | — | female |
| Janelle Cain | General Counsel | — | female |
| Kristine James | Chief Executive Officer of Medical Technology | — | female |
| Leonard Hansen | Chief Accountant & Chief Risk Officer | — | male |
| Martin Krauskopf | Chief Strategy & Corporate Development Officer | — | male |
| Mithran Naiker | Chief Information Officer | — | male |
| Simon Bunde | Executive General Manager of Strategic Operations, ESG & Innovation | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for EBO.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
